Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Conditions
Advanced Endometrial Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Beijing Obstetrics and Gynecology Hospital, Beijing, Beijing Municipality, China
Chongqing Cancer Hospital, Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
SUN Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Hunan Cancer Hospital, Changsha, Hunan, China
Xijing Hospital of Air Force Military Medical University, Xi'an, Shaanxi, China
Shandong Cancer Hospital, Jinan, Shandong, China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
Sencond Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin Municipality, China
Yunnan Cancer Hospital, Kunming, Yunnan, China
Women's Hospital school of Medical Zhejiang University, Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Study leads
Xiaohua Wu
Principal Investigator
Fudan University